Multiple IPOs have priced and additional offerings are scheduled through mid-October 2026, including Iambic Therapeutics and City Therapeutics biotech listings expected to raise roughly $150–175 million each. Year-to-date U.S. traditional IPO proceeds have already exceeded $120 billion, driven partly by large earlier deals such as SpaceX, while 254 IPOs have occurred through early October despite a slowdown in September. Investor selectivity persists amid volatility, with several sizable candidates like Firmus withdrawing, yet S-1 filings continue and SPAC activity has risen to its highest level since 2021. Biotech issuers have shown stronger aftermarket performance on average than broader IPO cohorts. Key near-term catalysts include the October 15–16 debuts and any additional filings or pricing announcements before year-end.